USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Altoris, Inc.
Address:
Altoris, Inc.
11575 Sorrento Valley Road
San Diego, CA 92121 0132
Phone:
(858) 453-9509
URL:
N/A
EIN:
450507294
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $543,844.00 3

Award List:

REGULATION OF STEROID HORMONES BY OXIDOREDUCTASES

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$185,910.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sex steroids play important roles in a number of cancers including breast, ovarian, endometrial and prostate cancers. In this proposal, we are planning to investigate means to modulate steroid levels in an effort to suppress tumor growth. During the Phase I of… More

INHIBITION OF DEHYDROGENASES FOR GLAUCOMA TREATMENT

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$176,419.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this proposal is the development a new class of pharmacological agents that modulate intraocular pressure by altering the levels of cortisol. Our approach consists of the design of inhibitors for an oxidoreductase that acts as a key… More

CORTISOL MODULATION BY OXIDOREDUCTASE INHIBITORS

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$181,515.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop a new class of pharmacological agents that aid in the management of different aspects of the metabolic syndrome by modulating the levels of cortisol. The compounds could also be of use in the management of… More